{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:59:46Z","timestamp":1789685986645,"version":"4.0.1"},"reference-count":72,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015755","name":"CIBERehd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Swallowed topical corticosteroids (STCs) are used as the first-line therapy for eosinophilic esophagitis (EoE) and have been extensively studied in randomized controlled trials (RCTs); however, the presentation and doses varied widely among the studies. Aim: The goal of this study was to compare the safety and effectiveness of the different STC-based options in EoE patients. Methods: We performed a literature search for RCTs, spanning a time period from database inception to July 2024, in order to compare the efficacy and safety of all STCs used to induce or maintain EoE remission each other and also with placebo or proton pump inhibitors (PPIs) in a network meta-analysis. Outcomes are expressed as pooled risk ratios (RRs) of failure and 95% confidence intervals (CIs), and we aimed to evaluate histological remission at &lt;15\u201320 eosinophils per high-power field (eos\/hpf), &lt;5\u20136 eos\/hpf, and &lt;1 eos\/hpf. The effect sizes for symptomatic improvement and the mean differences for endoscopic EREFS improvement with 95% CIs were also measured. Adverse events were evaluated using RRs, and these included oropharyngeal and esophageal candidiasis and adrenal suppression. Results: Twenty studies involving 1455 patients with active EoE reported on STC effectiveness to induce remission; three additional studies on 232 patients assessed the maintenance of remission. Budesonide 1 mg orodispersible tablets ranked highest in SUCRA in terms of all histological remission endpoints. Budesonide from inhalation devices was the only option superior to placebo in improving symptoms. Budesonide viscous suspension was the only option superior to placebo in improving endoscopy. No therapy was significantly associated with the risk of any adverse event. Significant inconsistencies and small study effects were detected in multiple comparisons. Conclusions: Budesonide orodispersible tablets were the best option for achieving EoE histological remission, but not symptomatic or endoscopic improvement. STC formulations were as safe as placebo or PPI.<\/jats:p>","DOI":"10.3390\/jcm14217823","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:13:08Z","timestamp":1762258388000},"page":"7823","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative Efficacy and Safety of Swallowed Topical Corticosteroids in Eosinophilic Esophagitis: A Network Meta-Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1072","authenticated-orcid":false,"given":"Alfredo J.","family":"Lucendo","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hospital General de Tomelloso, 13700 Tomelloso, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), 28029 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Castilla-La Mancha (IDISCAM), 45004 Toledo, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Princesa, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-0958","authenticated-orcid":false,"given":"\u00c1ngel","family":"Arias","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), 28029 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Castilla-La Mancha (IDISCAM), 45004 Toledo, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Princesa, 28006 Madrid, Spain"},{"name":"Research Unit, Hospital Universitario La Mancha Centro, 13600 Alc\u00e1zar de San Juan, Spain"},{"name":"Health Science Faculty-HM Hospitals, Camilo Jos\u00e9 Cela University, 28036 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6176-1618","authenticated-orcid":false,"given":"Celia","family":"\u00c1lvarez-Bueno","sequence":"additional","affiliation":[{"name":"Health and Social Research Center, Age-ABC Research Group, University of Castilla-La Mancha, 16002 Cuenca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6121-7893","authenticated-orcid":false,"given":"Vicente","family":"Mart\u00ednez-Vizcaino","sequence":"additional","affiliation":[{"name":"Health and Social Research Center, Age-ABC Research Group, University of Castilla-La Mancha, 16002 Cuenca, Spain"},{"name":"Facultad de Ciencias de la Salud, Universidad Aut\u00f3noma de Chile, Talca 3460000, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-0430","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Redondo-Cavero","sequence":"additional","affiliation":[{"name":"CarVasCare Research Group, Faculty of Nursing, University of Castilla-La Mancha, 16002 Cuenca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17474124.2019.1546120","article-title":"Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice","volume":"13","author":"Arias","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jama.2021.14920","article-title":"Eosinophilic Esophagitis: A Review","volume":"326","author":"Muir","year":"2021","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2050640616689525","article-title":"Guidelines on eosinophilic esophagitis: Evidence-based statements and recommendations for diagnosis and management in children and adults","volume":"5","author":"Lucendo","year":"2017","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.14309\/ajg.0000000000003194","article-title":"ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis","volume":"120","author":"Dellon","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.cgh.2023.01.019","article-title":"Efficacy of elimination diets in eosinophilic esophagitis: A systematic review and meta-analysis","volume":"21","author":"Mayerhofer","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/17474124.2020.1791084","article-title":"Dietary therapy for eosinophilic esophagitis: Chances and limitations in the clinical practice","volume":"14","author":"Lucendo","year":"2020","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2015.07.041","article-title":"Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis","volume":"14","author":"Lucendo","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/apt.15957","article-title":"Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: Results from the EoE connect registry","volume":"52","author":"Casabona","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.gastrohep.2020.07.010","article-title":"A meta-analysis of efficacy of topical steroids in eosinophilic esophagitis: From the perspective of histologic, clinical, and endoscopic outcome","volume":"44","author":"Hao","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF01296781","article-title":"Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome","volume":"38","author":"Attwood","year":"1993","journal-title":"Dig. Dis. Sci."},{"key":"ref_12","first-page":"1419","article-title":"Idiopathic eosinophilic esophagitis: A frequently overlooked disease with typical clinical aspects and discrete endoscopic findings","volume":"124","author":"Straumann","year":"1994","journal-title":"Schweiz. Med. Wochenschr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.gastrohep.2017.12.007","article-title":"Eosinophilic oesophagitis: Current evidence-based diagnosis and treatment","volume":"41","author":"Lucendo","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jaci.2021.07.001","article-title":"Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)","volume":"149","author":"Ma","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.anai.2020.03.021","article-title":"Technical review on the management of eosinophilic esophagitis: A report from the AGA institute and the joint task force on allergy-immunology practice parameters","volume":"124","author":"Rank","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ueg2.12533","article-title":"Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real-world efficacy from the EoE CONNECT registry","volume":"12","author":"Navarro","year":"2024","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_17","first-page":"90","article-title":"Treatment of eosinophilic esophagitis with inhaled corticosteroids","volume":"27","author":"Faubion","year":"1998","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/13543784.2022.2033207","article-title":"Current options and investigational drugs for the treatment of eosinophilic esophagitis","volume":"31","author":"Lucendo","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1055\/s-2007-966738","article-title":"Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid therapy: A case series","volume":"39","author":"Lucendo","year":"2007","journal-title":"Endoscopy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/j.1572-0241.2007.01379.x","article-title":"Oral viscous budesonide: A potential new therapy for eosinophilic esophagitis in children","volume":"102","author":"Aceves","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.14309\/ajg.0000000000001170","article-title":"Variability in Practices of Compounding Budesonide for Eosinophilic Esophagitis","volume":"116","author":"Joshi","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1053\/j.gastro.2006.08.033","article-title":"A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis","volume":"131","author":"Konikoff","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/apt.13537","article-title":"Systematic review with network meta-analysis: Comparative effectiveness of topical steroids vs. PPIs for the treatment of the spectrum of eosinophilic oesophagitis","volume":"43","author":"Lipka","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/MCG.0000000000001356","article-title":"A Network Meta-Analysis of Randomized Controlled Trials on the Treatment of Eosinophilic Esophagitis in Adults and Children","volume":"55","author":"Rokkas","year":"2021","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1136\/gutjnl-2023-329873","article-title":"Comparison of drugs for active eosinophilic oesophagitis: Systematic review and network meta-analysis","volume":"72","author":"Visaggi","year":"2023","journal-title":"Gut"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"ref_27","unstructured":"Higgins, J., Thomas, J., Chandler, T., Cumpston, M.L.T., Page, M.J., and Welch, V.A. (2022). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (Updated February 2022), Cochrane."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_29","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2020). Eosinophilic Esophagitis: Developing Drugs for Treatment Guidance for Industry."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/apt.12413","article-title":"Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis","volume":"38","author":"Dellon","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1053\/j.gastro.2014.08.028","article-title":"Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis","volume":"147","author":"Schoepfer","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1442-2050.2007.00670.x","article-title":"Validation of the Mayo Dysphagia Questionnaire","volume":"20","author":"Grudell","year":"2007","journal-title":"Dis. Esophagus"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00455-009-9246-8","article-title":"The Mayo Dysphagia Questionnaire-30: Documentation of reliability and validity of a tool for interventional trials in adults with esophageal disease","volume":"25","author":"McElhiney","year":"2010","journal-title":"Dysphagia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cgh.2011.01.017","article-title":"Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis","volume":"9","author":"Straumann","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"doab097","DOI":"10.1093\/dote\/doab097","article-title":"Validation of the Swedish Watson Dysphagia Scale for adult patients with eosinophilic esophagitis","volume":"35","author":"Albinsson","year":"2022","journal-title":"Dis. Esophagus"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/gutjnl-2011-301817","article-title":"Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: Validation of a novel classification and grading system","volume":"62","author":"Hirano","year":"2013","journal-title":"Gut"},{"key":"ref_37","first-page":"1","article-title":"Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring","volume":"30","author":"Collins","year":"2017","journal-title":"Dis. Esophagus"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2036.2011.04791.x","article-title":"The adult eosinophilic oesophagitis quality of life questionnaire: A new measure of health-related quality of life","volume":"34","author":"Taft","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"a1331","DOI":"10.1136\/bmj.a1331","article-title":"Drug eluting and bare metal stents in people with and without diabetes: Collaborative network meta-analysis","volume":"337","author":"Stettler","year":"2008","journal-title":"BMJ"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jval.2016.07.005","article-title":"Node-Splitting Generalized Linear Mixed Models for Evaluation of Inconsistency in Network Meta-Analysis","volume":"19","year":"2016","journal-title":"Value Health J. Int. Soc. Pharmacoecono. Outcomes Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: An introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern. Emerg. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Ioannidis JPA Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: Informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cgh.2007.11.008","article-title":"Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: A randomized trial in children","volume":"6","author":"Schaefer","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2010.05.001","article-title":"Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial","volume":"139","author":"Dohil","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s10620-009-0859-4","article-title":"Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis","volume":"55","author":"Peterson","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2010.07.048","article-title":"Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis","volume":"139","author":"Straumann","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.cgh.2012.03.018","article-title":"Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis","volume":"10","author":"Alexander","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/ajg.2012.443","article-title":"Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia","volume":"108","author":"Moawad","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.gastro.2014.04.019","article-title":"Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis","volume":"147","author":"Butz","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cgh.2014.05.021","article-title":"Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis","volume":"13","author":"Gupta","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/gutjnl-2014-308815","article-title":"A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis","volume":"65","author":"Miehlke","year":"2016","journal-title":"Gut"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.gastro.2016.11.021","article-title":"Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis","volume":"152","author":"Dellon","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.gastro.2019.03.014","article-title":"Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial","volume":"157","author":"Dellon","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","article-title":"Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial","volume":"157","author":"Lucendo","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.gastro.2012.04.049","article-title":"Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis","volume":"143","author":"Dellon","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/00365521.2021.1906314","article-title":"Topically applied mometasone furoate improves dysphagia in adult eosinophilic esophagitis\u2014Results from a double-blind, randomized, placebo-controlled trial","volume":"56","author":"Tytor","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cgh.2021.04.022","article-title":"Budesonide Oral Suspension Improves Outcomes in Patients with Eosinophilic Esophagitis: Results from a Phase 3 Trial","volume":"20","author":"Hirano","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S-227","DOI":"10.1016\/S0016-5085(24)01009-6","article-title":"960 Budesonide oral suspension is effective and safe as induction treatment of eosinophilic esophagitis in children and adolescents: Results from the randomized, double-blind, placebo-controlled induction phase of a multicenter pediatric trial (PEDEOS-1)","volume":"166","author":"Lucendo","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2020.07.039","article-title":"Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis","volume":"159","author":"Straumann","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/apt.15670","article-title":"Randomised clinical trial: The safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis","volume":"51","author":"Hirano","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.cgh.2021.06.020","article-title":"Long-Term Treatment of Eosinophilic Esophagitis with Budesonide Oral Suspension","volume":"20","author":"Dellon","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.cgh.2022.02.013","article-title":"Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial","volume":"20","author":"Dellon","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1097\/PAS.0000000000001361","article-title":"Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses from a 12-Week, Phase 2, Randomized, Placebo-controlled Trial","volume":"43","author":"Collins","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jgh.13281","article-title":"Topical steroids in eosinophilic esophagitis: Systematic review and meta-analysis of placebo-controlled randomized clinical trials","volume":"31","author":"Murali","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14656566.2022.2060077","article-title":"Drug treatment strategies for eosinophilic esophagitis in adults","volume":"23","author":"Lucendo","year":"2022","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1053\/j.gastro.2020.02.038","article-title":"AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/dote.12417","article-title":"Grade of eosinophilia versus symptoms in patients with dysphagia and esophageal eosinophilia","volume":"29","author":"Larsson","year":"2016","journal-title":"Dis. Esophagus"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7823\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T05:22:44Z","timestamp":1762406564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/21\/7823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":72,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14217823"],"URL":"https:\/\/doi.org\/10.3390\/jcm14217823","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}